NeoGenomics, Inc. (NEO) is a publicly traded Healthcare sector company. As of May 21, 2026, NEO trades at $8.90 with a market cap of $1.09B and a P/E ratio of 0.00. NEO moved +6.08% today. Year to date, NEO is -26.32%; over the trailing twelve months it is +11.39%. Its 52-week range spans $4.72 to $19.12. Analyst consensus is buy with an average price target of $14.94. Rallies surfaces NEO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What do analysts rate NEO?
11 analysts cover NEO: 0 strong buy, 8 buy, 3 hold, 0 sell, and 0 strong sell. The consensus rating is buy. The average price target is $14.94.